The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 24, 2024

Filed:

Feb. 26, 2021
Applicant:

Mereo Biopharma 3 Limited, London, GB;

Inventors:

Uwe Junker, Basel, CH;

Michaela Kneissel, Basel, CH;

Anthony Kent Hall, Oegstgeest, NL;

Rena Joy Eudy, West Hartford, CT (US);

Matthew Manning Riggs, Haddam, CT (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 31/663 (2006.01); A61K 39/00 (2006.01); A61P 19/08 (2006.01); C07K 16/22 (2006.01); A61K 38/22 (2006.01); A61K 38/29 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 31/663 (2013.01); A61K 39/3955 (2013.01); A61P 19/08 (2018.01); A61K 38/22 (2013.01); A61K 38/29 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01);
Abstract

Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.


Find Patent Forward Citations

Loading…